Astria Therapeutics, Inc. acquired by BioCryst for $13 per share, with the deal set to finalize in 1Q26. Click here to read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback